Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed May 1, 2017
Insider Transaction Report
Form 4
CHAMPSI FARAH
Director
Transactions
- Sale
Common Stock
2017-04-28$82.59/sh−2,617$216,138→ 4,962 total(indirect: See Footnote) - Sale
Common Stock
2017-04-27$82.77/sh−16,551$1,369,926→ 7,579 total(indirect: See Footnote)
Holdings
- 79,152
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $83.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F2]The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.